REYKJAVIK, November 6 deCODE genetics (Nasdaq:DCGN) today announced its consolidated financial results for the quarterended September 30, 2008. A conference call to discuss the quarter's ...
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery - our ...
At September 30, 2008, the company had liquid funds available for operating activities (cash and cash equivalents together with current investments) of $11.8 million, as compared to $23.7 million at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback